Investigators examined use of tapentadol, which has µ-opioid receptor agonist and norepinephrine reuptake inhibitor activity, for moderate-to-severe chronic osteoarthritis knee pain or low back pain.
There were no significant differences between tapentadol ER and a placebo or oxycodone CR in changes from baseline to endpoint in blood pressure or heart rate.
Read the Clinical Advisor on pain.
Related Articles on Pain Management:NIH Identifies 4 Key Areas for Record Amount of Pain Research Funding
5 Key Trends in Spine Pain Management From Dr. Vernon Williams
Hip Fracture Pain Reduced by Nerve Blockade, Study Finds